Suggested that the Government should collaborate with the Welsh Assembly on a project to improve cancer care across the UK, aiming to make life better for all constituents through united efforts. He congratulated Jim Shannon for securing the debate, praised Siobhain McDonagh's case on brain tumours, highlighted personal experiences with cancer, mentioned a decline in commercial trials and its financial impact, raised concerns about regional variation in uptake of innovative medicines. Asked about additional community diagnostic centres being set up in his constituency. Inquired into clinical trials, expressing concerns about the UK losing its competitive edge. He mentioned the unacceptable gap in medicines for cancer patients and the need to regain a higher position in global rankings. He also noted that there are 780 new cancer cases each day.

She requested a meeting to discuss solutions, which was positively received by the Minister.

She congratulated the hon. Member on securing the debate and highlighted the importance of medical radioisotopes for cancer diagnosis and treatment, mentioning a potential shortage in the UK. She suggested that Project ARTHUR at Trawsfynydd could provide a domestic supply of these isotopes. The proposal for a medical radioisotopes facility in north Wales would complement Bangor University's Nuclear Futures Institute and its planned new medical school. The centre for doctoral training in nuclear energy futures at Bangor has had its application for renewal rejected by the Engineering and Physical Sciences Research Council, which is concerning given the shortage of clinicians.

Discussed the importance of addressing cancer treatment challenges, emphasising the need for a united front to push for improvements in the appraisal process for licensed medicines and access to innovative treatments. He expressed concern about the impact of Brexit on the appraisal and distribution of cancer medicines, highlighting shortages and delays in Scotland. He noted that the Scottish Medicines Consortium must review new medicines before NHS prescription and that difficult choices have to be made due to finite resources. Owen Thompson also mentioned concerns over budget cuts at the MHRA and the withdrawal of pharmaceutical companies from the payback scheme. He discussed the impact of funding cuts on pharmaceutical companies, GPs, and patients, emphasising that clinical trials are down by 41% since 2016.

It seems crazy that in a system as universal as the NHS there should not be access to outcome data. South West London Elective Orthopaedic Centre at Epsom Hospital, being the largest hip and knee replacement centre outside of America, has the lowest blood risks, lowest infection rates, and quickest turnaround time. This centre keeps its own data, making £1 million a year from it which could potentially fund the latest cancer drugs. Those 91,000 did not include people suffering from a glioblastoma; there are no drugs available for them. Laura Nuttall, who passed away at the age of 22 after being diagnosed with a glioblastoma aged 18, highlighted that brain tumours are the greatest killer of people under the age of 40. Made a powerful speech advocating for better treatment options for brain tumours, highlighted her sister Margaret's struggle with the disease. Called on pharmaceutical companies to increase research in this area. She shared her personal experience with brain tumours, discussing drug availability on the NHS and survival rates. She underlined the need for more awareness and training in hospitals and for better outcomes.

Congratulates Jim Shannon on securing the debate, expressing gratitude for briefings received. Highlights issues with NICE's methods and processes for cancer drugs, noting survival rate disparities between the UK and US for glioblastoma. Acknowledges improvements in Kent and Medway's 62-day standard performance but expresses concern over access to new treatments due to changes in NICE's assessment process. Emphasises the importance of early diagnosis and data sharing to improve outcomes. She interjected briefly, sharing her personal experience of undergoing cancer treatment during the pandemic under hybrid working conditions. Tracey Crouch highlighted that this experience informed some of her contributions to the Procedure Committee. The pharmaceutical companies claim that a significant percentage—I cannot remember off the top of my head what it is—of drugs would not pass the test according to NICE's statistics. The Minister should meet with all interested parties, including pharmaceutical companies. She referenced the global survival rate for brain tumours, noting that it is 26% in the USA compared to just 10% in the UK. She also pointed out issues with early diagnosis and pharmaceutical companies.